

Mark Bolland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7403356/publications.pdf>

Version: 2024-02-01

272
papers

13,507
citations

31976
53
h-index

24258
110
g-index

282
all docs

282
docs citations

282
times ranked

12162
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized trial alerting authors, with or without coauthors or editors, that research they cited in systematic reviews and guidelines has been retracted. Accountability in Research, 2024, 31, 14-37.	2.4	5
2	Citation of retracted publications: A challenging problem. Accountability in Research, 2022, 29, 18-25.	2.4	31
3	Decreased thyroid FNA but increased ultrasound: Is the trade-off worthwhile?. Clinical Endocrinology, 2022, 96, 922-922.	2.4	0
4	Timeliness and content of retraction notices for publications by a single research group. Accountability in Research, 2022, 29, 347-378.	2.4	13
5	Dietary calcium intake and change in bone mineral density in older adults: a systematic review of longitudinal cohort studies. European Journal of Clinical Nutrition, 2022, 76, 196-205.	2.9	14
6	Diversity of invited speakers at endocrinology conferences. Clinical Endocrinology, 2022, 96, 907-913.	2.4	3
7	Nonoperative Management of Mild Primary Hyperparathyroidism: A Reasonable, Evidence-Based Option. Annals of Internal Medicine, 2022, , .	3.9	0
8	Correcting the scientific record – A broken system?. Accountability in Research, 2021, 28, 265-279.	2.4	10
9	Population vitamin D supplementation in UK adults: too much of nothing?. Drug and Therapeutics Bulletin, 2021, 59, 7-12.	0.3	2
10	Participant withdrawals were unusually distributed in randomized trials with integrity concerns: a statistical investigation. Journal of Clinical Epidemiology, 2021, 131, 22-29.	5.0	7
11	Clinical trial registry documents and publication integrity. Accountability in Research, 2021, 28, 149-161.	2.4	6
12	Vitamin D supplementation and testing in the UK: costly but ineffective?. BMJ, The, 2021, 372, n484.	6.0	8
13	Prevalence of biochemical osteomalacia in adults undergoing vitamin D testing. Clinical Endocrinology, 2021, 95, 74-83.	2.4	4
14	Identical summary statistics were uncommon in randomized trials and cohort studies. Journal of Clinical Epidemiology, 2021, 136, 180-188.	5.0	5
15	Participant injury in clinical trials conducted in New Zealand for the benefit of manufacturers: an unfair system?. New Zealand Medical Journal, 2021, 134, 124-131.	0.5	0
16	Vitamin D deficiency, supplementation and testing: have we got it right in New Zealand?. New Zealand Medical Journal, 2021, 134, 86-95.	0.5	0
17	Assessing and Raising Concerns About Duplicate Publication, Authorship Transgressions and Data Errors in a Body of Preclinical Research. Science and Engineering Ethics, 2020, 26, 2069-2096.	2.9	14
18	Check for publication integrity before misconduct. Nature, 2020, 577, 167-169.	27.8	64

#	ARTICLE	IF	CITATIONS
19	Empirically generated reference proportions for baseline p values from rounded summary statistics. <i>Anaesthesia</i> , 2020, 75, 1685-1687.	3.8	16
20	Nitrates Do Not Affect Bone Density or Bone Turnover in Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1040-1047.	2.8	6
21	Concerns About the Integrity of the Yamaguchi Osteoporosis Prevention Study (YOPS) Report, <i>Am J Med</i> . 2004;117:549-555. <i>American Journal of Medicine</i> , 2020, 133, e311-e314.	1.5	4
22	Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1641-e1647.	3.6	28
23	Calcium and/or Vitamin D Supplementation for the Prevention of Fragility Fractures: Who Needs It?. <i>Nutrients</i> , 2020, 12, 1011.	4.1	43
24	Predictors of Fracture in Older Women With Osteopenic Hip Bone Mineral Density Treated With Zoledronate. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 61-66.	2.8	8
25	Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 3-11.	2.8	14
26	Thyroid ultrasound and nodule malignancy risk: a "real world" assessment of ultrasound reporting and agreement of ultrasound-based malignancy risk estimates with cytology and histology findings. <i>New Zealand Medical Journal</i> , 2020, 133, 20-27.	0.5	1
27	25-Hydroxyvitamin D – Should labs be measuring it?. <i>Annals of Clinical Biochemistry</i> , 2019, 56, 188-189.	1.6	7
28	Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy. <i>Calcified Tissue International</i> , 2019, 105, 423-429.	3.1	3
29	Correcting Meta-analyses and Reviews Affected by Retracted Research. <i>JAMA Internal Medicine</i> , 2019, 179, 1005.	5.1	1
30	Controversies in medicine: the role of calcium and vitamin D supplements in adults. <i>Medical Journal of Australia</i> , 2019, 211, 468-473.	1.7	43
31	Vitamin D supplementation and musculoskeletal health – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 88-89.	11.4	3
32	Baseline P value distributions in randomized trials were uniform for continuous but not categorical variables. <i>Journal of Clinical Epidemiology</i> , 2019, 112, 67-76.	5.0	16
33	Rounding, but not randomization method, non-normality, or correlation, affected baseline P-value distributions in randomized trials. <i>Journal of Clinical Epidemiology</i> , 2019, 110, 50-62.	5.0	18
34	Publication rates after the first retraction for biomedical researchers with multiple retracted publications. <i>Accountability in Research</i> , 2019, 26, 277-287.	2.4	11
35	Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial. <i>Journal of Internal Medicine</i> , 2019, 286, 221-229.	6.0	21
36	Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least 11 Years in HIV-Infected Men. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1248-1253.	2.8	13

#	ARTICLE	IF	CITATIONS
37	Quality of reports of investigations of research integrity by academic institutions. Research Integrity and Peer Review, 2019, 4, 3.	5.2	23
38	An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature. BMJ Open, 2019, 9, e031909.	1.9	36
39	Evaluating ethics oversight during assessment of research integrity. Research Integrity and Peer Review, 2019, 4, 22.	5.2	1
40	Calcium supplementation in osteoporosis: useful or harmful?. European Journal of Endocrinology, 2018, 178, D13-D25.	3.7	55
41	Concerns About the Integrity of Sato et al. Am J Med. 2005;118:1250-1255. American Journal of Medicine, 2018, 131, e107-e108.	1.5	4
42	Reader response: Expression of Concern: Does compensatory hyperparathyroidism predispose to ischemic stroke? Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy; An alternative to vitamin D supplementation to prevent fractures in patients with MS; High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology, 2018, 90, 627-628.	1.1	1
43	Outcomes, Interventions and Funding in Randomised Research Published in High-Impact Journals. Trials, 2018, 19, 592.	1.6	3
44	Enough data to draw conclusions about vitamin D and bone health. BMJ: British Medical Journal, 2018, 363, k4755.	2.3	0
45	A randomised investigation of journal responses to academic and journalist enquiry about possible scientific misconduct. BMC Research Notes, 2018, 11, 521.	1.4	7
46	Fracture Prevention with Zoledronate in Older Women with Osteopenia. New England Journal of Medicine, 2018, 379, 2407-2416.	27.0	280
47	Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. Lancet Diabetes and Endocrinology, 2018, 6, 847-858.	11.4	303
48	Assessment of research waste part 2: wrong study populations- an exemplar of baseline vitamin D status of participants in trials of vitamin D supplementation. BMC Medical Research Methodology, 2018, 18, 101.	3.1	27
49	Assessment of research waste part 1: an exemplar from examining study design, surrogate and clinical endpoints in studies of calcium intake and vitamin D supplementation. BMC Medical Research Methodology, 2018, 18, 103.	3.1	9
50	A closer look at SCOOP: screening for fracture prevention. Lancet, The, 2018, 392, 551-552.	13.7	1
51	Revised Meta-analysis of Vitamin K and Fractures. JAMA Internal Medicine, 2018, 178, 1135.	5.1	2
52	Author response: Systematic review and statistical analysis of the integrity of 33 randomized controlled trials. Neurology, 2018, 90, 578-578.	1.1	0
53	Inaccurate retraction notice for meta-analysis by Iwamoto et al. Acta Neurologica Scandinavica, 2018, 138, 263-263.	2.1	2
54	Do vitamin D supplements help prevent respiratory tract infections?. BMJ: British Medical Journal, 2017, 356, j456.	2.3	13

#	ARTICLE	IF	CITATIONS
55	Neglect or good practice? Authorsâ€™ reply to letters by Rhein and Degner. BMJ: British Medical Journal, 2017, 356, j716.	2.3	0
56	Randomised trial assessing the impact of framing of fracture risk and osteoporosis treatment benefits in patients undergoing bone densitometry. BMJ Open, 2017, 7, e013703.	1.9	13
57	Cessation of strontium ranelate supply. BMJ: British Medical Journal, 2017, 357, j2580.	2.3	3
58	Maintaining Order in Osteoporosis Treatments. Journal of Bone and Mineral Research, 2017, 32, 1147-1147.	2.8	1
59	Conflicts of interest and expertise of independent commenters in news stories about medical research. Cmaj, 2017, 189, E553-E559.	2.0	11
60	Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. Cmaj, 2017, 189, E1130-E1136.	2.0	34
61	Are more trials of calcium supplements really needed?. Osteoporosis International, 2017, 28, 2729-2730.	3.1	1
62	Calcium Intake and Cardiovascular Disease Risk. Annals of Internal Medicine, 2017, 166, 684.	3.9	7
63	Further major uncorrected errors in National Osteoporosis Foundation meta-analyses of calcium and vitamin D supplementation in fracture prevention. Osteoporosis International, 2017, 28, 733-734.	3.1	7
64	Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ: British Medical Journal, 2017, 359, j4849.	2.3	320
65	Reporting of conflicts of interest in oral presentations at medical conferences: a delegate-based prospective observational study. BMJ Open, 2017, 7, e017019.	1.9	19
66	Calcium and Cardiovascular Disease. Endocrinology and Metabolism, 2017, 32, 339.	3.0	75
67	Review: Dietary or supplemental calcium increase BMD by 1.8% in persons >50 years of age. Annals of Internal Medicine, 2016, 164, JC5.	3.9	2
68	Management recommendations for osteoporosis in clinical guidelines. Clinical Endocrinology, 2016, 84, 687-692.	2.4	15
69	Ten years too long: strontium ranelate, cardiac events, and the European Medicines Agency. BMJ, The, 2016, 354, i5109.	6.0	21
70	Should adults take vitamin D supplements to prevent disease?. BMJ, The, 2016, 355, i6201.	6.0	28
71	Meta-analysis of randomised trials comparing a penicillin or cephalosporin with a macrolide or lincosamide in the treatment of cellulitis or erysipelas. Infection, 2016, 44, 607-615.	4.7	23
72	Systematic review and statistical analysis of the integrity of 33 randomized controlled trials. Neurology, 2016, 87, 2391-2402.	1.1	92

#	ARTICLE	IF	CITATIONS
73	We read spam a lot: prospective cohort study of unsolicited and unwanted academic invitations. BMJ, The, 2016, 355, i5383.	6.0	19
74	News coverage of clinical research. BMJ, The, 2016, 352, i1177.	6.0	2
75	Inaccurate dissemination of the MAVIDOS trial results. Lancet Diabetes and Endocrinology,the, 2016, 4, 481.	11.4	2
76	Errors in NOF meta-analyses of calcium and vitamin D supplements. Osteoporosis International, 2016, 27, 2637-2639.	3.1	5
77	Vitamin D supplements do not prevent falls. BMJ, The, 2016, 353, i3005.	6.0	3
78	Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes and Endocrinology,the, 2016, 4, 569-576.	11.4	151
79	Qualitative research, observational research, andThe BMJ. BMJ, The, 2016, 352, i1483.	6.0	2
80	Circulating calcium concentrations, vascular disease and mortality: a systematic review. Journal of Internal Medicine, 2016, 279, 524-540.	6.0	97
81	Outcomes of bone density measurements in coeliac disease. New Zealand Medical Journal, 2016, 129, 40-4.	0.5	3
82	Mendelian Randomization Analysis to Examine for a Causal Effect of Urate on Bone Mineral Density. Journal of Bone and Mineral Research, 2015, 30, 985-991.	2.8	50
83	Calcium supplements: benefits and risks. Journal of Internal Medicine, 2015, 278, 354-368.	6.0	101
84	Screening for Vitamin D Deficiency. Annals of Internal Medicine, 2015, 162, 736.	3.9	0
85	Different outcomes of meta-analyses and data inconsistency: response to comments by Pfeifer. Archives of Osteoporosis, 2015, 10, 43.	2.4	3
86	Evolution of Paget's disease of bone in adults inheriting <i><scp>SQSTM</scp>1</i> mutations. Clinical Endocrinology, 2015, 83, 315-319.	2.4	26
87	Reporting of Limitations of Observational Research. JAMA Internal Medicine, 2015, 175, 1571.	5.1	39
88	Web of industry, advocacy, and academia in the management of osteoporosis. BMJ, The, 2015, 351, h3170.	6.0	27
89	The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia, 2015, 58, 2238-2246.	6.3	104
90	Bone density is normal and does not change over 2Âyears in sarcoidosis. Osteoporosis International, 2015, 26, 611-616.	3.1	13

#	ARTICLE	IF	CITATIONS
91	Calcium intake and bone mineral density: systematic review and meta-analysis. BMJ, The, 2015, 351, h4183.	6.0	272
92	Calcium intake and risk of fracture: systematic review. BMJ, The, 2015, 351, h4580.	6.0	241
93	Should we prescribe calcium or vitamin D supplements to treat or prevent osteoporosis?. Climacteric, 2015, 18, 22-31.	2.4	44
94	Inconsistent data in text and tables. Osteoporosis International, 2015, 26, 2713-2713.	3.1	4
95	Vitamin D Supplements and the Risk of Falls. JAMA Internal Medicine, 2015, 175, 1723.	5.1	4
96	Cardiovascular Complications of Calcium Supplements. Journal of Cellular Biochemistry, 2015, 116, 494-501.	2.6	30
97	Calcium Supplements Increase Risk of Myocardial Infarction. Journal of Bone and Mineral Research, 2015, 30, 389-390.	2.8	14
98	Skeletal health in adults with HIV infection. Lancet Diabetes and Endocrinology,the, 2015, 3, 63-74.	11.4	36
99	Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial. Osteoporosis International, 2015, 26, 499-503.	3.1	37
100	Bone density in healthy men after cessation of calcium supplements: 20-month follow-up of a randomized controlled trial. Osteoporosis International, 2015, 26, 173-178.	3.1	1
101	Concordance of Results from Randomized and Observational Analyses within the Same Study: A Re-Analysis of the Women's Health Initiative Limited-Access Dataset. PLoS ONE, 2015, 10, e0139975.	2.5	10
102	Media Coverage, Journal Press Releases and Editorials Associated with Randomized and Observational Studies in High-Impact Medical Journals: A Cohort Study. PLoS ONE, 2015, 10, e0145294.	2.5	13
103	Are trials of vitamin D with mortality as an endpoint really needed?. BMJ, The, 2014, 349, g4452-g4452.	6.0	1
104	Press Releases Issued by Supplements Industry Organisations and Non-Industry Organisations in Response to Publication of Clinical Research Findings: A Case-Control Study. PLoS ONE, 2014, 9, e101533.	2.5	6
105	Authors' reply to MacDonald and Etminan. BMJ, The, 2014, 349, g5523-g5523.	6.0	0
106	Vitamin and Mineral Supplements in the Primary Prevention of Cardiovascular Disease and Cancer. Annals of Internal Medicine, 2014, 160, 655.	3.9	3
107	Calcium supplements associated with increased risk of cardiovascular death in men but not women. Evidence-based Nursing, 2014, 17, 90-90.	0.2	2
108	Response to letter to editor. Osteoporosis International, 2014, 25, 2501-2501.	3.1	0

#	ARTICLE	IF	CITATIONS
109	Differences in Overlapping Meta-Analyses of Vitamin D Supplements and Falls. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4265-4272.	3.6	53
110	A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record. BMJ Open, 2014, 4, e005787.	1.9	30
111	Calcium Supplements and Fracture Prevention. New England Journal of Medicine, 2014, 370, 386-388.	27.0	13
112	Correction for Lancet Diabetes Endocrinol 2014; 2: 573-80. Lancet Diabetes and Endocrinology, the, 2014, 2, e15.	11.4	0
113	Duration of Antiresorptive Effects of Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized, Placebo-Controlled Trial. Journal of Bone and Mineral Research, 2014, 29, 166-172.	2.8	21
114	Benefits of Calcium Supplements Are Too Small for Clinical Equipoise to Exist. Journal of Bone and Mineral Research, 2014, 29, 1914-1915.	2.8	1
115	Clinical Trial Evidence and Use of Fish Oil Supplements. JAMA Internal Medicine, 2014, 174, 460.	5.1	49
116	Vitamin D supplements and bone mineral density - Authors' reply. Lancet, The, 2014, 383, 1293-1294.	13.7	1
117	Calcium risk-benefit updated - New WHI analyses. Maturitas, 2014, 77, 1-3.	2.4	31
118	The Auckland calcium study: 5-year post-trial follow-up. Osteoporosis International, 2014, 25, 297-304.	3.1	25
119	Vitamin D supplementation and falls: a trial sequential meta-analysis. Lancet Diabetes and Endocrinology, the, 2014, 2, 573-580.	11.4	149
120	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes and Endocrinology, the, 2014, 2, 307-320.	11.4	371
121	Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet, The, 2014, 383, 146-155.	13.7	497
122	Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. American Journal of Clinical Nutrition, 2014, 100, 746-755.	4.7	229
123	Vitamin D and falls - Authors' reply. Lancet Diabetes and Endocrinology, the, 2014, 2, 541.	11.4	0
124	Unhelpful information about adverse drug reactions. BMJ, The, 2014, 349, g5019-g5019.	6.0	52
125	Skeletal and nonskeletal effects of vitamin D: is vitamin D a tonic for bone and other tissues?. Osteoporosis International, 2014, 25, 2347-2357.	3.1	43
126	The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. European Journal of Endocrinology, 2014, 170, 255-262.	3.7	37

#	ARTICLE	IF	CITATIONS
127	Republished: Paget's disease of bone: clinical review and update. Postgraduate Medical Journal, 2014, 90, 328-331.	1.8	1
128	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes – Authors' reply. Lancet Diabetes and Endocrinology, 2014, 2, 364-365.	11.4	9
129	Vitamin D supplements do not reduce mortality risk. BMJ, 2014, 348, g2860-g2860.	6.0	4
130	Results of Observational Studies: Analysis of Findings from the Nurses' Health Study. PLoS ONE, 2014, 9, e110403.	2.5	21
131	A Case Study of Discordant Overlapping Meta-Analyses: Vitamin D Supplements and Fracture. PLoS ONE, 2014, 9, e115934.	2.5	47
132	Translation of research into clinical practice: a case study of calcium supplement prescribing in New Zealand. New Zealand Medical Journal, 2014, 127, 94-101.	0.5	3
133	Diagnostic category agreement and malignancy rates in clinician-categorised, non-standardised thyroid cytology reports. New Zealand Medical Journal, 2014, 127, 49-55.	0.5	0
134	Calcium supplements and cardiovascular risk in the Women's Health Initiative. Osteoporosis International, 2013, 24, 2371-2372.	3.1	4
135	Testosterone Levels Following Decreases in Serum Osteocalcin. Calcified Tissue International, 2013, 93, 133-136.	3.1	15
136	A pooled analysis of Vitamin D dose requirements for fracture prevention. IBMS BoneKEy, 2013, 10, .	0.0	3
137	Antiretroviral Preexposure Prophylaxis for HIV Prevention. New England Journal of Medicine, 2013, 368, 82-84.	27.0	31
138	The effect of treatments for osteoporosis on mortality. Osteoporosis International, 2013, 24, 1-6.	3.1	45
139	Comment on Kanis et al.: Pitfalls in the external validation of FRAX. Osteoporosis International, 2013, 24, 389-390.	3.1	9
140	The impact of dietary calcium intake and vitamin D status on the effects of zoledronate. Osteoporosis International, 2013, 24, 349-354.	3.1	20
141	Calcium supplements and cancer risk: a meta-analysis of randomised controlled trials. British Journal of Nutrition, 2013, 110, 1384-1393.	2.3	81
142	Calcium supplements and cardiovascular risk: 5 years on. Therapeutic Advances in Drug Safety, 2013, 4, 199-210.	2.4	55
143	Strontium and cardiovascular events. Annals of the Rheumatic Diseases, 2013, 72, e22-e22.	0.9	3
144	Paget's disease of bone: clinical review and update. Journal of Clinical Pathology, 2013, 66, 924-927.	2.0	47

#	ARTICLE	IF	CITATIONS
145	Randomised controlled trial of vitamin D supplementation in sarcoidosis. <i>BMJ Open</i> , 2013, 3, e003562.	1.9	33
146	Discrepancies in predicted fracture risk in elderly people. <i>BMJ</i> , The, 2013, 346, e8669-e8669.	6.0	28
147	Subgroup analysis for the risk of cardiovascular disease with calcium supplements. <i>BoneKEy Reports</i> , 2013, 2, 293.	2.7	15
148	Low-dose Fluoride in Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2301-2307.	3.6	20
149	Differences between self-reported and verified adverse cardiovascular events in a randomised clinical trial. <i>BMJ Open</i> , 2013, 3, e002334.	1.9	16
150	What is the appropriate MHRA regulatory response to calcium's increased cardiovascular risk?. <i>BMJ</i> , The, 2013, 346, f3413-f3413.	6.0	1
151	Convicted at a Show Trial. <i>British Journalism Review</i> , 2013, 24, 19-23.	0.0	0
152	Observational studiesâ€™just telling us what we want to hear or telling us where we need to look?. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 980-983.	2.8	1
153	Nonsustained hypercalcaemia and primary hyperparathyroidism in the <scp>PEARS</scp> cohort. <i>Clinical Endocrinology</i> , 2013, 79, 899-899.	2.4	0
154	An inappropriate response?. <i>BMJ</i> , The, 2013, 346, f942-f942.	6.0	3
155	Authors' reply to McCloskey and colleagues. <i>BMJ</i> , The, 2013, 346, f1440-f1440.	6.0	0
156	Calcium and cardiovascular risks. <i>Australian Prescriber</i> , 2013, 36, 148-149.	1.0	0
157	Reply to RT Chlebowski et al. <i>American Journal of Clinical Nutrition</i> , 2012, 95, 259.	4.7	1
158	Vitamin D Dose Requirements for Fracture Prevention. <i>New England Journal of Medicine</i> , 2012, 367, 1367-1370.	27.0	6
159	Calcium supplements: bad for the heart?. <i>Heart</i> , 2012, 98, 895-896.	2.9	36
160	Calcium supplements and cardiovascular risk. <i>Nature Reviews Cardiology</i> , 2012, 9, 497-498.	13.7	7
161	Comment: Assessing the Potential Adverse Consequences of Supplemental Calcium on Cardiovascular Outcomes: Should We Change Our Approach to Bone Health?. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1267-1268.	1.9	0
162	Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial. <i>European Journal of Endocrinology</i> , 2012, 166, 1087-1091.	3.7	43

#	ARTICLE	IF	CITATIONS
163	Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least Five Years in HIV-Infected Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1922-1928.	3.6	50
164	Severe Vitamin D Deficiency: A Prerequisite for Chronic Obstructive Pulmonary Disease Responsiveness to Vitamin D Supplementation?. <i>Annals of Internal Medicine</i> , 2012, 156, 904.	3.9	0
165	Low-Dose Zoledronate in Osteopenic Postmenopausal Women. <i>Obstetrical and Gynecological Survey</i> , 2012, 67, 349-350.	0.4	0
166	Vitamin D testing. <i>Lancet, The</i> , 2012, 379, 1699.	13.7	3
167	Vitamin D testing. <i>Lancet, The</i> , 2012, 379, 1699-1700.	13.7	2
168	Vitamin D and tuberculosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E3528-E3528.	7.1	2
169	Calcium Supplements and Risk of Myocardial Infarction: An Hypothesis Twice Tested. <i>American Journal of Medicine</i> , 2012, 125, e15.	1.5	10
170	Effect of osteoporosis treatment on mortality. <i>Bone</i> , 2012, 50, S27.	2.9	0
171	Five years of anti-resorptive effects after 1 or 2 doses of zoledronate â€” Data from 2 randomized controlled trials. <i>Bone</i> , 2012, 50, S46-S47.	2.9	1
172	Five years of anti-resorptive activity after a single dose of zoledronate â€” Results from a randomized double-blind placebo-controlled trial. <i>Bone</i> , 2012, 50, 1389-1393.	2.9	83
173	Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 286-292.	3.6	43
174	Role of vitamin D deficiency in cardiovascular disease. <i>Heart</i> , 2012, 98, 609-614.	2.9	38
175	Vitamin D and health in adults in Australia and New Zealand: a position statement. <i>Medical Journal of Australia</i> , 2012, 197, 553-553.	1.7	3
176	Misclassification does not explain increased cardiovascular risks of calcium supplements. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 959-959.	2.8	9
177	Stable bone mineral density over 6â€”years in HIVâ€”infected men treated with highly active antiretroviral therapy (HAART). <i>Clinical Endocrinology</i> , 2012, 76, 643-648.	2.4	24
178	Should measurement of vitamin D and treatment of vitamin D insufficiency be routine in New Zealand?. <i>New Zealand Medical Journal</i> , 2012, 125, 83-91.	0.5	3
179	Calcium and vitamin D supplements and health outcomes: a reanalysis of the Womenâ€™s Health Initiative (WHI) limited-access data set. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 1144-1149.	4.7	243
180	Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. <i>BMJ: British Medical Journal</i> , 2011, 342, d2040-d2040.	2.3	740

#	ARTICLE	IF	CITATIONS
181	Calcium supplementation: Balancing the cardiovascular risks. Maturitas, 2011, 69, 289-295.	2.4	34
182	Authors' response to editorial. BMJ: British Medical Journal, 2011, 342, d3520-d3520.	2.3	5
183	Decreased bone density in men on methadone maintenance therapy. Addiction, 2011, 106, 349-354.	3.3	53
184	Management of primary hyperparathyroidism. Clinical Endocrinology, 2011, 75, 722-722.	2.4	0
185	Mortality and morbidity in Cushing's syndrome in New Zealand. Clinical Endocrinology, 2011, 75, 436-442.	2.4	149
186	Calcium supplements and cardiovascular disease - picking the spin. International Journal of Clinical Practice, 2011, 65, 226-227.	1.7	3
187	Cardiovascular effects of calcium supplementation. Osteoporosis International, 2011, 22, 1649-1658.	3.1	93
188	Re: The calcium scare: what would Austin Bradford Hill have thought?. Osteoporosis International, 2011, 22, 3079-3080.	3.1	8
189	Familial Paget Disease and SQSTM1 Mutations in New Zealand. Calcified Tissue International, 2011, 89, 258-264.	3.1	13
190	Evaluation of the FRAX and Garvan fracture risk calculators in older women. Journal of Bone and Mineral Research, 2011, 26, 420-427.	2.8	158
191	Calcium supplements and cardiovascular risk. Journal of Bone and Mineral Research, 2011, 26, 899-899.	2.8	8
192	Stable Bone Density in HAART-Treated Individuals with HIV: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2721-2731.	3.6	68
193	Vitamin D Supplementation and Fracture Risk—Reply. Archives of Internal Medicine, 2011, 171, 265.	3.8	0
194	Fracture-risk calculators: Has their time come?. Cmaj, 2011, 183, 171-172.	2.0	3
195	Prevalent dietary supplement use in older New Zealand men. New Zealand Medical Journal, 2011, 124, 55-62.	0.5	4
196	Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis. Obstetrical and Gynecological Survey, 2010, 65, 514-515.	0.4	2
197	Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction. Journal of Bone and Mineral Research, 2010, 25, 505-512.	2.8	74
198	Response to publication of PRISM trial. Journal of Bone and Mineral Research, 2010, 25, 1463-1464.	2.8	9

#	ARTICLE	IF	CITATIONS
199	Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial. Journal of Bone and Mineral Research, 2010, 25, 2251-2255.	2.8	57
200	Relationships between vascular calcification, calcium metabolism, bone density, and fractures. Journal of Bone and Mineral Research, 2010, 25, 2777-2785.	2.8	83
201	Investigating harms in clinical trials - no easy task. International Journal of Clinical Practice, 2010, 64, 1719-1722.	1.7	1
202	Does calcium supplementation increase cardiovascular risk?. Clinical Endocrinology, 2010, 73, 689-695.	2.4	73
203	Morbidity and mortality in mild primary hyperparathyroidism. Clinical Endocrinology, 2010, 73, 688-688.	2.4	1
204	Evidence From Randomized Controlled Trials, Meta-analyses, and Subgroup Analyses. JAMA - Journal of the American Medical Association, 2010, 303, 1253.	7.4	3
205	Skeletal Effects of Interventions in Mild Primary Hyperparathyroidism: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1653-1662.	3.6	85
206	Effects of calcium supplementation on lipids, blood pressure, and body composition in healthy older men: a randomized controlled trial. American Journal of Clinical Nutrition, 2010, 91, 131-139.	4.7	91
207	Evidence From Randomized Controlled Trials, Meta-analyses, and Subgroup Analyses. JAMA - Journal of the American Medical Association, 2010, 303, 1253.	7.4	10
208	Vitamin D Supplementation. Archives of Internal Medicine, 2010, 170, 572.	3.8	2
209	Vitamin D insufficiency and health outcomes over 5 y in older women. American Journal of Clinical Nutrition, 2010, 91, 82-89.	4.7	119
210	Disparate Outcomes from Applying U.K. and U.S. Osteoporosis Treatment Guidelines. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1856-1860.	3.6	36
211	Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1174-1181.	3.6	285
212	Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ: British Medical Journal, 2010, 341, c3691-c3691.	2.3	931
213	Benefits of Vitamin D?. American Journal of Medicine, 2010, 123, e17.	1.5	0
214	"Cherry picking" did not occur in studied example. BMJ: British Medical Journal, 2010, 341, c5009-c5009.	2.3	3
215	Reporting of absolute risk. BMJ: British Medical Journal, 2010, 341, c6331-c6331.	2.3	1
216	Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ: British Medical Journal, 2010, 341, c6923-c6923.	2.3	1

#	ARTICLE	IF	CITATIONS
217	Vitamin D Deficiency and Its Health Consequences in New Zealand. , 2010, , 589-601.		0
218	Trials of Vertebroplasty for Vertebral Fractures. New England Journal of Medicine, 2009, 361, 2097-2100.	27.0	47
219	The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 538-544.	3.6	100
220	Effect of calcium supplementation on hip fractures: reply to correspondence. Osteoporosis International, 2009, 20, 835-836.	3.1	4
221	Calcium supplementation for older men and women?. Osteoporosis International, 2009, 20, 2147-2148.	3.1	2
222	Is calcium supplementation a risk factor for cardiovascular diseases in older women?. Nutrition Reviews, 2009, 67, 424-424.	5.8	2
223	Effective osteoporosis treatments reduce mortality: A meta-analysis. Bone, 2009, 44, S38.	2.9	0
224	Do Calcium Supplements Lead to an Increase in Coronary Calcification?. Heart Lung and Circulation, 2009, 18, S28-S29.	0.4	0
225	Role of ultrasound in the assessment of nodular thyroid disease. Journal of Medical Imaging and Radiation Oncology, 2009, 53, 177-187.	1.8	55
226	The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. Obstetrical and Gynecological Survey, 2009, 64, 462-463.	0.4	1
227	Time for a moratorium on vitamin D meta-analyses?. BMJ: British Medical Journal, 2009, 339, b4394-b4394.	2.3	15
228	Trials of vertebroplasty for vertebral fractures. New England Journal of Medicine, 2009, 361, 2098-9; author reply 2099-100.	27.0	15
229	Effect of calcium supplementation on hip fractures. Osteoporosis International, 2008, 19, 1119-1123.	3.1	111
230	Osteomalacia in an HIV-infected man receiving rifabutin, a cytochrome P450 enzyme inducer: a case report. Annals of Clinical Microbiology and Antimicrobials, 2008, 7, 3.	3.8	12
231	Effects of Intravenous Zoledronate on Bone Turnover and BMD Persist for at Least 24 Months. Journal of Bone and Mineral Research, 2008, 23, 1304-1308.	2.8	41
232	Paget disease of bone. Trends in Endocrinology and Metabolism, 2008, 19, 246-253.	7.1	52
233	Bilateral Transient Osteoporosis of the Hip in a Young Man. Journal of Clinical Densitometry, 2008, 11, 339-341.	1.2	12
234	Calcium supplementation and vascular disease. Climacteric, 2008, 11, 280-286.	2.4	22

#	ARTICLE	IF	CITATIONS
235	Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2008, 336, 262-266.	2.3	585
236	The effect of calcium supplementation on serum urate: analysis of a randomized controlled trial. <i>Rheumatology</i> , 2008, 48, 195-197.	1.9	26
237	Randomized Controlled Trial of Calcium Supplementation in Healthy, Nonosteoporotic, Older Men. <i>Archives of Internal Medicine</i> , 2008, 168, 2276.	3.8	122
238	A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. <i>European Journal of Endocrinology</i> , 2008, 159, 89-95.	3.7	409
239	Artifact in the control group undermines the conclusions of a vitamin D and cancer study. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 792-792.	4.7	14
240	Does degree of baldness influence vitamin D status?. <i>Medical Journal of Australia</i> , 2008, 189, 674-675.	1.7	19
241	Calcium supplementation and cancer incidence. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 792-793.	4.7	12
242	Calcium supplementation does not increase mortality. <i>Medical Journal of Australia</i> , 2008, 189, 55-56.	1.7	1
243	Prospective 10-year study of postmenopausal women with asymptomatic primary hyperparathyroidism. <i>New Zealand Medical Journal</i> , 2008, 121, 18-29.	0.5	4
244	The effects of seasonal variation of 25-hydroxyvitamin D on diagnosis of vitamin D insufficiency. <i>New Zealand Medical Journal</i> , 2008, 121, 63-74.	0.5	44
245	Low Body Weight Mediates the Relationship between HIV Infection and Low Bone Mineral Density: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4522-4528.	3.6	118
246	The Peroxisome Proliferator-Activated Receptor- γ Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1305-1310.	3.6	399
247	Annual Zoledronate Increases Bone Density in Highly Active Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Men: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1283-1288.	3.6	119
248	Bone Formation Markers in Adults with Mild Osteogenesis Imperfecta. <i>Clinical Chemistry</i> , 2007, 53, 1109-1114.	3.2	22
249	The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. <i>American Journal of Clinical Nutrition</i> , 2007, 86, 959-964.	4.7	173
250	Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. <i>Bone</i> , 2007, 41, 318-320.	2.9	332
251	Age-, gender-, and weight-related effects on levels of 25-hydroxyvitamin D are not mediated by vitamin D binding protein. <i>Clinical Endocrinology</i> , 2007, 67, 259-264.	2.4	73
252	Bone mineral density remains stable in HAART-treated HIV-infected men over 2Âyears. <i>Clinical Endocrinology</i> , 2007, 67, 270-275.	2.4	49

#	ARTICLE	IF	CITATIONS
253	Delayed Development of Paget's Disease in Offspring Inheriting SQSTM1 Mutations. Journal of Bone and Mineral Research, 2007, 22, 411-415.	2.8	73
254	The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporosis International, 2007, 18, 479-486.	3.1	115
255	Vitamin D sufficiency: reply to letter by Heaney. Osteoporosis International, 2007, 18, 835-836.	3.1	1
256	The randomised controlled trial to meta-analysis ratio: original data versus systematic reviews in the medical literature. New Zealand Medical Journal, 2007, 120, U2804.	0.5	3
257	Randomized Controlled Trial of Calcium in Healthy Older Women. American Journal of Medicine, 2006, 119, 777-785.	1.5	249
258	Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. Bone, 2006, 38, 317-321.	2.9	126
259	Osteonecrosis of the jaw and bisphosphonates. BMJ: British Medical Journal, 2006, 333, 1122.3-1123.	2.3	1
260	Gastrointestinal stromal tumour in succinate dehydrogenase subunit B mutation-associated familial pheochromocytoma/paraganglioma. ANZ Journal of Surgery, 2006, 76, 763-764.	0.7	17
261	Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. Clinical Endocrinology, 2006, 65, 191-197.	2.4	45
262	Determinants of vitamin D status in older men living in a subtropical climate. Osteoporosis International, 2006, 17, 1742-1748.	3.1	70
263	A case of low cortisol-binding globulin: use of plasma free cortisol in interpretation of hypothalamic-pituitary-adrenal axis tests. Annals of Clinical Biochemistry, 2006, 43, 237-239.	1.6	19
264	Osteonecrosis of the jaw and bisphosphonates—putting the risk in perspective. New Zealand Medical Journal, 2006, 119, U2339.	0.5	5
265	Determinants of vitamin D status in older women living in a subtropical climate. Osteoporosis International, 2005, 16, 1641-1648.	3.1	121
266	Association between Primary Hyperparathyroidism and Increased Body Weight: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1525-1530.	3.6	183
267	Effects of a β -Blocker on Bone Turnover in Normal Postmenopausal Women: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5212-5216.	3.6	97
268	Evaluation and Treatment of Primary Hyperparathyroidism. JAMA - Journal of the American Medical Association, 2005, 294, 2699-2700.	7.4	1
269	Heterophile antibodies may cause falsely lowered serum cortisol values. Journal of Endocrinological Investigation, 2005, 28, 643-645.	3.3	27
270	Cushing's Syndrome Due to Interaction Between Inhaled Corticosteroids and Itraconazole. Annals of Pharmacotherapy, 2004, 38, 46-49.	1.9	90

#	ARTICLE	IF	CITATIONS
271	Antioxidant supplements for preventing gastrointestinal cancers. , 2004, , CD004183.		31
272	Bilateral Femoral Head Osteonecrosis After Septic Shock and Multiorgan Failure. Journal of Bone and Mineral Research, 2003, 19, 517-520.	2.8	15